MACUGEN® PROFESSIONAL RESOURCES ARE AVAILABLE

The following materials can help you learn more about MACUGEN® and help educate patients in your practice

Order MACUGEN® for your patients

ORDER

Answers to patient frequently asked questions

What's the difference between wet and dry AMD?

Wet AMD starts out as dry AMD. Dry AMD is the early form in which proteins build up in the retina. Scientists think that the body recognizes that the dry AMD is disrupting the circulation of blood in the eye, preventing oxygen and nutrients from reaching the retina. In response, a growth factor is triggered, which causes blood vessels to grow in the eye, leading to wet AMD.

How common is wet AMD?

AMD is a progressive eye condition affecting more than 2 million Americans and millions more around the world. Although just 10% to 15% of AMD cases are the wet type, these cases account for 90% of all vision loss caused by AMD.

How do I know I need MACUGEN®?

Your doctor will work with you to determine if MACUGEN® is an appropriate treatment for you. For more information, speak with your doctor.

Can MACUGEN® cure wet AMD?

There is currently no cure for wet AMD. Wet AMD is a serious condition that can progress to a loss of your central vision. With treatment, this loss of vision can often be slowed.

What are the most common side effects with MACUGEN®?

The following side effects were reported by 10% to 40% of patients treated with MACUGEN® for up to two years in clinical studies: eye swelling, blurred vision, cataract, increased redness in the white of the eye, discharge from the eye, eye irritation, eye pain, high blood pressure, increased eye pressure, eye discomfort, visual disturbances, burning sensation, redness, light sensitivity, and vision loss.

Eye injections may have side effects. Be sure to ask your retina specialist about these before treatment.

How is MACUGEN® administered and how often?

MACUGEN® is given by eye injection. Your doctor will schedule eye injections every 6 weeks or will customize a maintenance schedule based on your needs. In the days following MACUGEN® administration, you may be at risk for the development of endophthalmitis (inflammation of the inner coats of the eye due to an infection). If the eye becomes red, sensitive to light, painful, or develops a change in vision, contact your doctor immediately so you can be treated early if an infection occurs.

What if I need help with the cost of MACUGEN®?

The Focus on Access (FOA) program is a valuable resource for eligible patients and may help you with the cost of your MACUGEN® treatment.

FOA can help eligible patients secure access to MACUGEN®.

Patients may also receive reimbursement counseling.

Patients and physicians complete a form and FOA will provide a timely response.

TO LEARN MORE call the FOCUS ON ACCESS Hotline, 1 (866) 272-8838

Indication

MACUGEN® (pegaptanib sodium injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration.

Important Safety Information

  • MACUGEN® (pegaptanib sodium injection) is contraindicated in patients with ocular or periocular infections, and in patients with known hypersensitivity to pegaptanib sodium or any other excipient in this product.
  • Intravitreous injections, including those with MACUGEN®, have been associated with endophthalmitis. Proper aseptic injection technique should always be utilized when administering MACUGEN®. In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur.
  • Increases in intraocular pressure have been seen within 30 minutes of injection with MACUGEN®. Therefore, intraocular pressure as well as the perfusion of the optic nerve head should be monitored and managed appropriately.
  • Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in post-marketing experience following the MACUGEN® intravitreal administration procedure.
  • Serious adverse events related to the injection procedure occurring in <1% of intravitreous injections included endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.
  • Most common adverse reactions (reported in 10-40% of patients treated with MACUGEN® for up to two years) are anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities.

Click here for full Prescribing Information for MACUGEN®.

Reference: 1. MACUGEN [package insert], Bausch & Lomb Incorporated.

Indication and Important Safety Information